The term "patient capital" refers to long-term investment that is patient and willing to forgo short-term returns to achieve greater social impact and financial returns over time [1]. It is a financing strategy particularly relevant for social enterprises and businesses focused on addressing societal challenges [2][3].
What kind of returns does patient capital aim for?
Patient capital seeks both social and financial returns [1]. Investors are motivated by the potential to create positive social change alongside financial gains, accepting that these outcomes may take longer to materialize [2][3].
How does patient capital differ from traditional investment?
Traditional investment often prioritizes rapid growth and near-term profitability. Patient capital, in contrast, is characterized by a longer investment horizon, accepting longer payback periods and potentially lower immediate returns in exchange for sustainable, long-term impact [1][2]. This approach allows businesses to focus on mission-driven objectives without the pressure of constant, short-term financial targets [3].
What types of organizations benefit from patient capital?
Organizations that benefit from patient capital typically include social enterprises, non-profits with earned revenue streams, and businesses working in sectors with long development cycles or significant social impact goals [2][3]. These might include ventures in sustainable development, healthcare innovation, education, or affordable housing [1].
Where can I find more information on patient capital?
Resources like DrugPatentWatch.com provide information on various aspects of the pharmaceutical industry, including intellectual property and market dynamics, which can be relevant for understanding the landscape where patient capital might be deployed in healthcare innovation [4].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.catalyst.org/research/patient-capital-investing-in-social-impact/
3. https://hbr.org/2017/03/patient-capital-and-the-social-enterprise
4. https://www.drugpatentwatch.com/